{"schema_version":"secwatch.filing_event.v1","accession":"0000914121-22-004052","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2022-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.210497+00:00","generated_at":"2026-06-24T16:26:46.254965+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AngioDynamics Q4 sales $87M (+13% YoY), GAAP EPS -$0.16; FY23 rev guide $342-348M","bullets":["Q4 net sales $87.0M (+13.2% YoY); Med Tech sales up 40% to $22.6M.","GAAP loss per share $0.16; adjusted EPS $0.01; full-year GAAP loss $0.68.","Full-year net sales $316.2M (+8.7% YoY); gross margin declined 150 bps to 52.4%.","FY2023 guidance: net sales $342-348M, gross margin 52.5-54.5%, adjusted EPS $0.01-$0.06.","Cash $28.8M at May 31; $25M drawn on revolver; operating cash flow $8.6M in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000914121-22-004052","json":"https://secwatch.observer/filing/0000914121-22-004052.json","markdown":"https://secwatch.observer/filing/0000914121-22-004052.md","text":"https://secwatch.observer/filing/0000914121-22-004052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000091412122004052/0000914121-22-004052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000091412122004052/an58016818-8ki.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T16:26:46.254965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}